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ment costs in insulin-naive patients following initiation of therapy
with either insulin glargine (IG) or insulin detemir (ID) over 1-year
time horizon from a payers’ perspective in Argentina. Methods: We
used a pharmacoeconomic model based on a randomized trial
comparing IG and ID (Rosenstock J, Davies M, Home PD, et al. A
randomised, 52-week, treat-to-target trial comparing insulin detemir
with insulin glargine when administered as add-on to glucose-
lowering drugs in insulin-naive people with type 2 diabetes. Diabeto-
logia 2008;51:408–16) and Argentinean sources. Clinical, resource use,
and cost data were combined to estimate direct medical costs (insulin,
test strips, and needles) during the ﬁrst year. Price per international
unit of insulin is similar for IG and ID in the local market. Determin-
istic analysis was performed on insulin unit cost and probabilistic
sensitivity analyses on clinical, resource use, and unit costs to
evaluate contribution to variance on the difference in total annualee front matter Copyright & 2014, International S
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Aires, Argentina.treatment cost. Results: Annual mean treatment cost (Argentinean
pesos 2013) was AR $6229 for IG and AR $9257 for ID, showing 33%
total cost reduction with IG (AR $3028; exchange rate US $1.00 ¼ AR
$5.30). Probabilistic sensitivity analysis showed that IG was cost
saving in 88% of the simulations. The most inﬂuential parameter
was the difference in insulin dose requirements. Threshold analysis
showed that if the unit price of ID is reduced by 43%, ceteris paribus, the
total annual costs per person for both insulin regimens would be
the same. Conclusions: From a payer’s perspective in Argentina, cost
savings related to the use of IG represented one third of total treatment
costs. Sensitivity analyses conﬁrmed the robustness of these results.
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diabetes.
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Type 2 diabetes mellitus (T2DM) is a serious public health problem
due to its high prevalence and the development of chronic compli-
cations (retinopathy, nephropathy, peripheral vascular disease, ulcers,
diabetic foot and amputations, cardiovascular disease, and stroke),
which increases resource use and socioeconomic costs, especially in
developed countries [1]. The economic burden raised by diabetes is
challenging health care systems. According to the World Health
Organization, direct health care cost of diabetes-related illnesses
ranged from 5% to 13% of a country’s annual health care budget,
depending on local prevalence and treatment costs [2]. In Argentina,
diabetes affects 11.9% of the population [3] and is estimated to
represent a high proportion of total health expenditure [2].
It has been clearly established that the development and
progression of complications can be effectively prevented or
delayed through tight glycemic control [4–6]. A number oflandmark randomized controlled trials and meta-analysis of
randomized controlled trials (RCTs) established that intensive
glucose-lowering treatment reduces microvascular complica-
tions, and follow-up data from these studies suggest that inten-
sive treatment also lowers macrovascular risk in T2DM [5,7–11].
When considering effectiveness, tolerability, and cost of the
various diabetes treatments, insulin is not only the most potent
but also the most cost-effective intervention [12,13].
In spite of the existing evidence, there has been a stepwise
introduction of glucose-lowering interventions, with the ﬁnal
step of insulin therapy being administered 10 to 15 years after
diagnosis [14]. Both patients and physicians are often reluctant to
start insulin because of fears of painful injections, hypoglycemia,
and weight gain [15–17]. In recent years, long-acting insulin
analogues, insulin glargine (IG) and insulin detemir (ID), were
introduced and proposed as a therapeutic alternative with the
potential to overcome some of these barriers as data from trialsociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Table 1 – Clinical parameters.
Parameter Insulin
glargine
Insulin detemir
Once daily
injection
Twice daily
injection
Initial mean body
weight (kg)
87.4 87.4 87.4
Final weight (kg)* 91.3 89.7 91.1
Initial doses (IU) 12 12 12
Final doses (IU/kg) 0.44 0.52 1
Average dose (IU) 26.09 29.32 51.55
Note. Estimated and adapted from Rosenstock et al. [22].
* This indicator was calculated adding to the initial mean body
weight the mean change registered at the end of the trial for each
insulin scheme.
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and nocturnal hypoglycemia in patients treated with either IG or
ID compared with neutral protamine hagedorn (NPH) insulin [18].
According to the American Diabetes Association and the Euro-
pean Association for the Study of Diabetes guidelines for the
management of T2DM, insulin could be initiated with either once-
daily NPH insulin or long-acting insulin analogues [19]. Regimes
involving long-acting insulin analogues can achieve clinically
important improvements in glycemic control similar to those
achieved with NPH, but with less risk of hypoglycemia [20,21].
Studies that compared IG and ID in patients with T2DM
showed that both analogues did not differ in efﬁcacy and safety
proﬁles [22–25].
The economic impact of the use of these insulins was
estimated in Spain by Guisasola et al. [26] on the basis of the
only 52-week randomized trial to date (Rosenstock et al.) [22],
which compared clinical outcomes related to the addition of
basal insulin analogues ID or IG in a sample of 582 insulin-naive
patients with T2DM who were inadequately controlled with oral
glucose-lowering drugs. In this study, it was found that the use of
IG instead of ID would result in annual saving on treatment costs
of 34% or 534.96 (€ 2006) for a patient with T2DM.
Pscherer et al. [27] compared treatment costs of IG with those
of ID, both combined with bolus insulin as part in patients with
T2DM in Germany. The authors concluded that IG may represent
a cost-saving option for patients with T2DM in this country, with
potential annual cost savings of €684 (19%) per patient compared
with ID at 2008 prices.
In contrast, a retrospective cohort analysis of health care claims
data in a large USmanaged care organization (since May to December
2006) found that patients receiving ID incurred lower diabetes-related
medical costs ($707 vs. $1510; P ¼ 0.03) and total health care costs
($2261 vs. $3408; P ¼ 0.03) than did those using IG [28].
We found many other similar cost comparison studies
between these insulins for many countries [26,27,36], but none
of them was for any Latin American country. The Latin-American
Diabetes Association guidelines recommend the use of insulin
analogues when hypoglycemia is limiting glycemic control [29].
Up to date, no studies in Latin America have compared the
economic impact of the use of IG versus ID.
This study attempts to estimate and compare the economic
implications of IG and ID therapy initiation in insulin-naive
patients with T2DM with 1-year time horizon, from a payer’s
perspective in Argentina incorporating a probabilistic sensitivity
analysis (PSA).Methods
We used a pharmacoeconomic exercise based on Guisasola et al.
[26], and Pscherer et al. [27] constructed on MS Excel based on the
results of Rosenstock et al. [22]. Although other trials comparing
the efﬁcacy and safety of both insulin have been published [23–
25], the study by Rosenstock et al. [22] is the only trial to date that
compared IG and ID in an annual duration of treatment in
insulin-naive patients with T2DM.
Clinical, resource use, and cost data were combined in the
model to estimate annual direct medical costs associated with
the use of insulin, test strips, and needles required during the
ﬁrst year of insulin treatment in T2DM.
Clinical Parameters
Table 1 lists the clinical parameters for each insulin regime. At
the end of follow-up, 55% of the patients treated with ID required
twice-daily application. All patients treated with IG required
once-daily injections.This trial informed the initial and ﬁnal doses of each insulin
regimen, so an average total dose per each insulin regimen was
estimated on the basis of the initial dose (12 international unit
[IU] for all patients) and the ﬁnal dose per insulin regimen
reported in Rosenstock et al. [22] considering a linear titration
over the 52 weeks. This is a conservative assumption, given that
80% of the patients requiring ID twice daily (n ¼ 103) were
transferred to this scheme during the ﬁrst 12 weeks of treatment.
Average total dose
¼ Initial dose per kgþ Final dose per kgInitial dose per kg
2
 
 Final body weight
As the equation shows, mean dose per each insulin regimen was
calculated using patient’s ﬁnal weight. As in Rosenstock et al.
[22], only the mean initial and incremental body weight from
baseline at 52th week were reported and the ﬁnal body weight
was estimated as the initial plus the incremental one. As in the
case of the average total dose, this estimation was also a
conservative assumption for IG because the ﬁnal body weight
estimated was higher for IG than for ID per each insulin regime.
Because the difference in hypoglycemic events was neither
clinical nor statistically signiﬁcant among both regimens (0.04
episodes per patient-year) [22], it was not considered in the model.
Costs associated with the change in body weight of each
insulin regimen are a relatively new issue and usually not
included in the literature, and they were not considered in ours
because of the difﬁculty in identifying an unbiased cost estimate
for the Argentinean context.
Utilization of Resources and Cost Parameters
The commercial forms considered for insulins were Lantus Solo-
star and Levemir FlexPen for IG and ID, respectively. This
decision is based on the fact that both presentations are the only
ones available in the Argentinean market that contain the same
quantity of insulin (ﬁve preﬁlled pens of 3 mL with 100 IU/mL).
In relation to the use of needles, we assumed a utilization rate
of one per each insulin application. Finally, regarding the use of
test strips, a consumption rate of three and six units per week for
once-daily and twice-daily injection scheme, respectively, was
assumed. Both assumptions were based on expert opinion of
diabetes specialists. It is recognized that a lower number of
applications may have advantages in terms of quality of life,
but this issue will not be considered in monetary terms in this
cost comparison exercise because it is out of scope of this article
and because of the absence of local estimates.
Monetary values for insulins were obtained from the Argenti-
nean market. Unit prices for the commercial forms considered
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both valid since April 30, 2013. To customize the situation to our
perspective, a 35% discount over market prices was used, assum-
ing the presence of purchase power from large payers. Unit costs
for test strips and needles were obtained from the Argentinean
market; we considered Accu-chek active glucose per 50 strips
from ROCHE (AR $6.4656 per strip) and Novoﬁne 30 G 100 and 70
(AR $1.5574 per needle). All unit prices and costs include value-
added tax and are expressed in local currency, year 2013 (mean
exchange rate US $1.00 ¼ AR $5.30).
Annual costs were calculated for insulins, needles, and test
strips. For each insulin, the cost per unit of insulin was multiplied
by the corresponding average total dose, estimated by the equa-
tion, and by 365 days of treatment. Regarding needles and test
strips, total annual costs for IG were calculated by multiplying the
unit price per the utilization rate and 365; for ID, these were
calculated in the same way as in the IG regimen up to the 12th
week, and for the remaining 40 weeks, they were calculated in a
similar way but ponderating by the proportion of people with once-
daily and twice-daily dose, as expressed in the following equation:
12 7Unit CostUse1ð Þþ 40 7ð Þ  %1 Unit CostUse1ð Þ½
þ %2 Unit CostUse2ð Þ
where Use1 and Use2 refer to the utilization rate for those on a
once-daily and twice-daily dose scheme with ID, respectively, and
%1 and %2 refer to the proportion of people on a once-daily and
twice-daily dose scheme with ID.
Sensitivity Analysis
Base-case values with their corresponding distributions, associ-
ated parameters, and commentaries are expressed in Table 2.
Deterministic analysis was performed to evaluate the change inTable 2 – Probabilistic sensitivity analysis: Variables, dis
Variable Base
value
Distribution Param
Final dose per kilogram for
insulin glargine (IU/kg)
0.44 Normal Mean ¼
SD ¼ 0
Min ¼
Final dose per kilogram for
once-daily injection for
insulin detemir (IU/kg)
0.52 Normal Mean ¼
SD ¼ 0
Min ¼
Final dose per kilogram for
twice-daily injection for
insulin detemir (IU/kg)
1 Normal Mean ¼
SD ¼ 0
Min ¼
Completers with once-daily
injections with insulin
detemir (%)
45% Beta Min ¼
Max ¼
α ¼ 1
β ¼ 1
Discount over unit price of
insulins (%)
35% Beta Min ¼
Max ¼
α ¼
β ¼
Unit cost of test strips (AR $) 6.4656 Normal Min ¼
Max ¼
Mean ¼
SD ¼ 3.
Unit cost of needle (AR $) 1.5574 Normal Min ¼
Max ¼
Mean ¼
SD ¼ 0.
IU, international unit; max, maximum; min, minimum.the unit price of ID so as to get a null difference in the total annual
costs per person for each insulin regimen. Then, PSA was per-
formed using Monte-Carlo technique and considering 1950 iter-
ations at a conﬁdence level of 95% for mean and SD; this number
of trials was enough to reach an accurate forecast for our results.
Final doses of insulin in units per kilogram (IU/kg) were simulated
under a normal distribution considering as base-case values those
reported in Rosenstock et al. [22], with an inferior limit of 0.15 IU/kg
[19], assuming a common SD of 50% for each regimen, which equals
0.22 IU/kg, 0.26 IU/kg, and 0.50 IU/kg for IG, ID once-daily, and ID
twice-daily dose scheme, respectively. Because Rosenstock et al. [22]
did not inform measures of dispersion for insulin doses, the propor-
tion for the SD of ﬁnal doses of insulin was based on Raskin et al. [25].
The proportion of patients treated with ID receiving once-
daily dose was assumed to follow a beta distribution. Unit prices
of insulins were not included in the PSA; instead, the discount
over both market prices was included, assuming it to be similar
for both insulins. The distribution type and parameters for this
variable were derived from experts’ opinion.
Unit costs for test strips and needles are both assumed to
follow a normal distribution considering as base-case values
those from the sources already mentioned; the SD in both cases
was assumed to be 50%.Results
The overall annual treatment costs (insulin, needles, and test
strips) per person in the ﬁrst year were AR $6229 and AR $9257 for
IG and ID, respectively (Table 3). The insulin component repre-
sented 75% of the total treatment cost for both insulin regimens.
Although unit prices of insulins were very similar, treatment oftributions, and parameters.
eters Comments
0.44 Mean extracted from Rosenstock et al. [22]. SD was
assumed equal to 50% based on Raskin et al. [25].
Minimum value was assumed according to general
local practice.
.22
0.15
0.52 As above
.26
0.15
1.00 As above
.50
0.15
0% Parameters extracted from Rosenstock et al. [22].
Completers with twice-daily injections were calculated
as 1 minus this variable.
100%
05
29
15% Parameters were set to shape local expert’s opinion.
50%
5
4
0 Extracted from Argentinean market. SD assumed to reach
50% according to personal communication with experts.50
6.46
2328
0 Extracted from Argentinean market. SD assumed to reach
50% according to personal communication with experts.50
1.55
7787
Table 3 – Base case: Total annual costs per treatment.
Annual costs ( AR $) Insuline glargine Insulin detemir Difference (insulin detemir – insulin glargine)
Insulin 4649.43 7008.68 2359.24
Test strips 1011.40 1439.66 428.25
Needles 568.45 809.15 240.70
Total 6229.29 9257.48 3028.19
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with T2DM initiating ID, mainly due to daily doses requirement.
The results of a deterministic threshold analysis indicated
that if the unit price of ID net of the discount was reduced by 43%
of its original, ceteris paribus, the total annual costs per person for
both insulin regimens in the base case would be the same. This
price reduction would be enough to offset those savings gener-
ated by the IG regime on needles and on self-monitoring blood
glucose costs.
In the PSA, the estimated mean value for the difference in
total annual treatment costs between IG and ID under a lognor-
mal distribution was marginally higher than the estimated value
in the base case (AR $3114.6 vs. AR $3028.2). Fig. 1 shows density
and cumulative distributions, respectively, for the difference in
total annual treatment cost. This difference was positive, mean-
ing that IG was cost saving, in 87% of the simulations.
Table 4 summarizes the sensitivity of the results (correlation
and contribution to variance) of the assumptions made in the
model, that is, the inﬂuence of each variable incorporated into
PSA over mean difference in total annual treatment costs. In our
estimations, ﬁnal doses per kilogram of both insulin regimens
were main determinants for the variance in our result. All these
variables had the expected sign and the expected strength over
them. As shown, variations in the ﬁnal doses (IU/kg) of ID had a
growing effect over the variance in our result as we moved from
once-daily dose to twice-daily dose scenarios.0
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Fig. 1 – Probabilistic sensitivity analysis: Density and cumulativ
detemir – insulin glargine). Density and cumulative distributions
of iterations, respectively.Discussion
In our study, mean total annual costs in the ﬁrst year after
initiating insulin treatment among insulin-naive patients with
T2DM were lower when treated with IG than with ID, AR $6229
and AR $9257 for IG and ID, respectively (Table 3). But when
patients were treated with once-daily dose of ID or IG, such
difference narrowed in a signiﬁcant way (5%).
Because the unit prices of commercial forms used for both
insulins were similar, this difference in cost was mainly
explained by the difference in insulin dose requirement. Costs
were also higher in the ID group for strips and needles, mainly as
a result of twice-daily dosing in 55% of the patients who initiate
insulin therapy with ID.
Costs associated with hypoglycemic events and other compli-
cations were not accounted for in this analysis because the
difference in hypoglycemic events was neither clinical nor
statistically signiﬁcant among both regimens in the trial [22].
Studies suggest that higher doses of insulin are required for
patients with T2DM when using ID than when using other basal
insulins [30–32]. Higher requirements of insulin doses for ID (0.82
IU/kg vs. 0.59 IU/kg) were observed in a 52-week target-to-treat
trial that compared IG versus ID efﬁcacy and safety in a basal-
bolus regimen with mealtime insulin as part in patients with
T2DM [23]. Similar results were found in a 24-week treat-to-target$ 4,772 $ 7,784 $10,495
87%
e distributions of difference on total annual costs (insulin
are plotted in relation to the absolute and relative frequency
Table 4 – Probabilistic sensitivity analysis: Multi-
variable correlation to and contribution to variance
on difference on total annual costs.
Variable Correlation* Contribution
to variance
Final dose for twice-daily
injection for ID (IU/kg)
0.741522 0.550503
Final dose for IG (IU/kg) 0.58027 (0.337116)
Final dose for once-daily
injection for ID (IU/kg)
0.310636 0.096609
Unit cost of test strips
(AR $)
0.094218 0.008888
Unit cost of needle (AR $) 0.061392 0.003773
Discount over unit price of
insulins
0.04462 (0.001993)
Completers (%) with once-
daily dose of ID
0.03341 (0.001117)
ID, insulin detemir; IG, insulin glargine; IU, international unit.
* Rank correlation estimates between each variable and the
difference in total annual costs (ID vs. IG).
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[24]. Raskin et al. [25], however, showed no differences in insulin
doses (0.70 vs. 0.67) in the subgroup of insulin-naive patients with
T2DM when treated with insulin as part in a basal-bolus regimen.
A study conducted in Argentina that included 607 insulin-
treated patients with T2DM followed by diabetes specialists
showed that 82% of 51 patients treated with IG received one
daily dose and 18% two daily doses. Regarding ID, 66% of 45
patients received two daily doses and 34% only one daily dose.
Mean daily doses of insulin reported in this study were 30.7 
17.9 UI/d for IG and 36.1  23.8 UI/d for ID; no distinction was
made for patients who received one or two daily injections [33].
Although once-daily and twice-daily insulin regimens for IG and
ID were similar to those reported in Rosenstock et al. [22], the
mean daily dose of ID differed. In Rosenstock et al. [22], this value
doubled the dose reported in this study.
The reasons for the increased dose requirement for ID are not
clear, but it is likely to be related to the pharmacologic properties
of the analogue [34,35].
We decided to include in our study the only RCT that
evaluated clinical outcomes in insulin-naive patients with
T2DM treated with IG and ID as add-on therapy to glucose-
lowering agents. We excluded trials using less rigorous methods,
such as quasi-experimental studies or nonrandomized studies
because RCTs provide stronger and more unbiased estimations of
the effect of interventions. We also decided not to use the study
that described insulin therapy in Argentina because it has an
observational design and included a small number of patients
with IG and ID treated by diabetes specialists. This restriction
clearly limited the eligibility of studies for this exercise to only
one RCT with 582 participants.
Our results are consistent with those described in cost
comparison studies in other countries and with a cohort study
in which patients with T2DM who initiated a basal-bolus insulin
regimen with IG had reduced costs of treatment than did those
treated with ID in UK routine general practice [36]. In this study,
the median cost of prescriptions for classiﬁable antidiabetic
therapy was 28.1% lower among those treated with IG than in
those treated with ID (£1014 vs. £1410), a difference of £397 per
person-year. The largest single contribution to this difference
arose from the difference in insulin cost (32% lower), reagent cost
(16% lower), pen delivery devices (50% lower), and sharps (16%
lower) in the IG group compared with the ID group.These ﬁndings may have coverage and policy implications. As
studies to date show that ID and IG have similar efﬁcacy [22,24],
at similar commercial unit cost, treatment with IG over ID would
be preferred in insulin-naive patients with T2DM as part of a
basal-bolus regimen because this decision could achieve a sub-
stantial cost saving. Our results based on the study by Rosenstock
et al. [22] state that per 1000 patients treated with IG, an overall
cost saving per year of AR $3,028,190 could be expected. Also, in
the case that a broader perspective as the societal one was
considered, this difference in cost would probably be higher,
due to the extra time and discomfort associated with a more
frequent dosing scheme of ID [37].
Further research, however, needs to be undertaken to eval-
uate real-world utilization, the long-term cost and cost-effec-
tiveness of IG over ID, as well as the consistency of the ﬁnding of
different dosing requirements between these insulins in our
country. Our ﬁndings analyze treatment costs in insulin-naive
patients with T2DM during the ﬁrst year of initiating a therapy
with either IG or ID.
This study estimated the annual difference in treatment cost
of ID and IG schemes in patients with T2DM in Argentina.
Initiating insulin treatment with IG in patients with T2DM was
associated with lower costs compared with ID use. T2DM requires
substantially higher doses of ID, which translates into higher
insulin costs
From a payer’s perspective, cost savings related to the use of
IG represented one third of total treatment costs. Sensitivity
analyses conﬁrmed the robustness of these results.Acknowledgment
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